FY2026 EPS Estimates for Arcus Biosciences, Inc. Lifted by Analyst (NYSE:RCUS)

Arcus Biosciences, Inc. (NYSE:RCUSGet Rating) – Analysts at Wedbush boosted their FY2026 earnings per share (EPS) estimates for Arcus Biosciences in a research note issued on Wednesday, May 11th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $14.22 per share for the year, up from their prior forecast of $13.96.

A number of other equities research analysts have also recently commented on the stock. Truist Financial increased their target price on shares of Arcus Biosciences from $70.00 to $77.00 in a research report on Friday, February 25th. Zacks Investment Research cut shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 1st. The Goldman Sachs Group cut their price objective on shares of Arcus Biosciences from $45.00 to $43.00 in a research report on Thursday, January 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research report on Friday, April 1st. Finally, TheStreet raised shares of Arcus Biosciences from a “d” rating to a “c” rating in a research note on Monday, March 21st. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $60.86.

Shares of NYSE RCUS opened at $17.23 on Thursday. The firm has a 50-day simple moving average of $30.81 and a 200-day simple moving average of $35.03. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 40.07 and a beta of 1.00. Arcus Biosciences has a 52 week low of $16.74 and a 52 week high of $49.10.

Arcus Biosciences (NYSE:RCUSGet Rating) last issued its earnings results on Monday, May 9th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($1.79). Arcus Biosciences had a net margin of 13.80% and a return on equity of 7.96%. During the same quarter last year, the firm earned ($1.08) earnings per share.

In other news, COO Jennifer Jarrett sold 9,617 shares of the firm’s stock in a transaction that occurred on Wednesday, March 16th. The shares were sold at an average price of $31.62, for a total value of $304,089.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.30% of the company’s stock.

A number of large investors have recently modified their holdings of RCUS. EcoR1 Capital LLC raised its holdings in Arcus Biosciences by 53.6% during the third quarter. EcoR1 Capital LLC now owns 5,122,359 shares of the company’s stock worth $178,617,000 after purchasing an additional 1,787,112 shares in the last quarter. BlackRock Inc. raised its holdings in Arcus Biosciences by 4.1% during the third quarter. BlackRock Inc. now owns 4,202,960 shares of the company’s stock worth $146,558,000 after purchasing an additional 164,232 shares in the last quarter. BVF Inc. IL raised its holdings in Arcus Biosciences by 15.4% during the third quarter. BVF Inc. IL now owns 3,229,822 shares of the company’s stock worth $112,624,000 after purchasing an additional 432,000 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Arcus Biosciences by 0.4% in the 4th quarter. Woodline Partners LP now owns 1,706,425 shares of the company’s stock valued at $69,059,000 after acquiring an additional 7,312 shares during the period. Finally, Pictet Asset Management SA increased its holdings in shares of Arcus Biosciences by 9.8% in the 4th quarter. Pictet Asset Management SA now owns 1,648,990 shares of the company’s stock valued at $66,735,000 after acquiring an additional 147,762 shares during the period. 73.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile (Get Rating)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

Featured Articles

Earnings History and Estimates for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.